STOCK TITAN

Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) announced CEO Jonathan Drachman will join a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 8:00 a.m. ET. The event will feature a live audio webcast, accessible through the investor section of Neoleukin's website, along with an archived replay available for 30 days post-event. Neoleukin specializes in immunotherapies for cancer and autoimmune diseases through its innovative de novo protein design technology, with its lead candidate being NL-201, a combined IL-2 and IL-15 agonist.

Positive
  • None.
Negative
  • None.

SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.

A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Safe Harbor / Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com


FAQ

When is the Canaccord Genuity 41st Annual Growth Conference for Neoleukin Therapeutics?

The conference is scheduled for August 11, 2021, at 8:00 a.m. Eastern Time.

Who will represent Neoleukin at the Canaccord conference?

Jonathan Drachman, M.D., CEO of Neoleukin Therapeutics, will participate in the conference.

Where can I watch the Neoleukin Therapeutics conference presentation?

The presentation will be available live via audio webcast on Neoleukin's investor website.

What is NL-201 from Neoleukin Therapeutics?

NL-201 is a combined IL-2 and IL-15 agonist aimed at improving tolerability and activity in immunotherapy.

How long will the Neoleukin conference replay be available?

An archived replay of the conference will be available for at least 30 days after the event.

Neoleukin Therapeutics, Inc.

:NLTX

NLTX Rankings

NLTX Latest News

NLTX Stock Data

8.20M
1.36M
0.28%
Biotechnology
Healthcare
Link
United States
Seattle